Eledon Pharmaceuticals (Nasdaq: ELDN) announced several clinical development milestones for its investigational drug tegoprubart, an anti-CD40L antibody, across kidney and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA